Authorized health care providers should now order the monoclonal antibody therapy bamlanivimab and antibody cocktail casirivimab/imdevimab directly from the sole distributor, AmerisourceBergen Corp., the Department of Health and Human Services announced Friday.

HHS’ Office of the Assistant Secretary for Preparedness and Response will no longer allocate the therapies to health departments because the drugs are no longer in short supply, the agency said, noting that the products remain free of charge to requesting sites. “HHS will continue to monitor all direct orders, and we retain the capacity to resume allocation of these and future therapies if needed.” For more on the direct ordering process, see the ASPR guide.

The Food and Drug Administration in November issued emergency use authorizations for bamlanivimab and casirivimab/imdevimab to treat certain COVID-19 outpatients at risk for severe disease.

Related News Articles

Headline
The departments of Health and Human Services and Defense yesterday announced an agreement to purchase at least 105 million doses of a Pfizer omicron-…
Headline
The Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response and Food and Drug Administration this week…
Headline
The Food and Drug Administration today announced it has revoked the emergency use authorizations for the Simoa Semi-Quantitative SARS-CoV-2 IgG Antibody…
Headline
The Centers for Disease Control and Prevention last night endorsed Moderna’s COVID-19 vaccine for children aged 6-17, as its advisory committee…
Headline
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices today unanimously recommended Moderna’s COVID-19 vaccine for…
Blog
A recent article in the Washington Post “COVID bailout rescued some hospitals while enriching others” is wrong. The reality is that all of America’s hospitals…